GSK-3 inhibitor IX   Click here for help

GtoPdb Ligand ID: 5974

Synonyms: 6-bromoindirubin-3-oxime | BIO | BRW | indirubin deriv. 7a
Compound class: Synthetic organic
Comment: This is compound 7a in [8]. It is a synthetic analogue of 6-bromoindirubin isolated from the Mediterranean mollusc Hexaplex trunculus [6].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 1
Topological polar surface area 73.72
Molecular weight 355
XLogP 3.19
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES ONC1=c2ccccc2=NC1=C1C(=O)Nc2c1ccc(c2)Br
Isomeric SMILES ONC1=c2ccccc2=N/C/1=C/1\C(=O)Nc2c1ccc(c2)Br
InChI InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,20,22H,(H,19,21)/b15-13-
InChI Key WNWSUJQVZJJGLF-SQFISAMPSA-N
References
1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]
2. Cai Z, Zhao Y, Zhao B. (2012)
Roles of glycogen synthase kinase 3 in Alzheimer's disease.
Curr Alzheimer Res, 9 (7): 864-79. [PMID:22272620]
3. Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, Krebs EG. (1999)
Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice.
Diabetes, 48 (8): 1662-6. [PMID:10426388]
4. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013)
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Biochem J, 451 (2): 313-28. [PMID:23398362]
5. Hurtado DE, Molina-Porcel L, Carroll JC, Macdonald C, Aboagye AK, Trojanowski JQ, Lee VM. (2012)
Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
J Neurosci, 32 (21): 7392-402. [PMID:22623685]
6. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R et al.. (2003)
GSK-3-selective inhibitors derived from Tyrian purple indirubins.
Chem Biol, 10 (12): 1255-66. [PMID:14700633]
7. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR. (2000)
Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.
Diabetes, 49 (2): 263-71. [PMID:10868943]
8. Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M et al.. (2004)
Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
J Med Chem, 47 (4): 935-46. [PMID:14761195]
9. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. (1993)
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.
Proc Natl Acad Sci USA, 90 (16): 7789-93. [PMID:8356085]